Fig. 3 (abstract P567).
From: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Incidence of Grade 3-5 Adverse Events Nivolumab
Fig. 3 (abstract P567). | Journal for ImmunoTherapy of Cancer